Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
Stock Summary
Financial details
Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
| Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Revenue per share | 505.09 | 561.41 | 580.23 | 619.64 | 723.97 | |
| Net income per share | 97 | 100.25 | 118.47 | 151.11 | 161.32 | |
| Operating cash flow per share | 30.34 | 129.88 | 147.14 | 148.21 | 123.87 | |
| Free cash flow per share | -27.22 | 72.3 | 102.61 | 107.55 | 99.28 | |
| Cash per share | 165.47 | 139.01 | 199.25 | 210.31 | 234.34 | |
| Book value per share | 1.01K | 1.08K | 1.12K | 1.27K | 1.31K | |
| Tangible book value per share | 914.18 | 971.91 | 995.26 | 1.14K | 1.2K | |
| Share holders equity per share | 1.01K | 1.08K | 1.12K | 1.27K | 1.31K | |
| Interest debt per share | 1.44 | 4.57 | 18.27 | 18.41 | 19.39 | |
| Market cap | 1313.86B | 1069.11B | 1305.8B | 1373.13B | 1639.67B | |
| Enterprise value | 1249.3B | 1011.33B | 1245.16B | 1321.13B | 1579.36B | |
| P/E ratio | 26.13 | 20.74 | 21.87 | 18.21 | 20.36 | |
| Price to sales ratio | 5.02 | 3.7 | 4.47 | 4.44 | 4.54 | |
| POCF ratio | 83.54 | 16.01 | 17.61 | 18.56 | 26.52 | |
| PFCF ratio | -93.11 | 28.76 | 25.25 | 25.58 | 33.09 | |
| P/B Ratio | 2.51 | 1.92 | 2.32 | 2.16 | 2.5 | |
| PTB ratio | 2.51 | 1.92 | 2.32 | 2.16 | 2.5 | |
| EV to sales | 4.77 | 3.5 | 4.26 | 4.27 | 4.37 | |
| Enterprise value over EBITDA | 17.1 | 13.35 | 13.17 | 11.31 | 12.79 | |
| EV to operating cash flow | 79.44 | 15.15 | 16.79 | 17.86 | 25.54 | |
| EV to free cash flow | -88.53 | 27.21 | 24.08 | 24.61 | 31.87 | |
| Earnings yield | 0.04 | 0.05 | 0.05 | 0.05 | 0.05 | |
| Free cash flow yield | -0.01 | 0.03 | 0.04 | 0.04 | 0.03 | |
| Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.13 | 0.14 | 0.16 | 0.14 | 0.1 | |
| Net debt to EBITDA | -0.88 | -0.76 | -0.64 | -0.45 | -0.49 | |
| Current ratio | 3.06 | 2.34 | 2.47 | 2.64 | 4.27 | |
| Interest coverage | 1.69K | 413.4 | 91.7 | 717.74 | 118.07 | |
| Income quality | 0.31 | 1.3 | 1.24 | 0.98 | 0.77 | |
| Dividend Yield | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | |
| Payout ratio | 0.47 | 0.42 | 0.38 | 0.3 | 0.34 | |
| Sales general and administrative to revenue | 0.26 | 0.24 | 0.23 | 0.22 | 0.21 | |
| Research and developement to revenue | 0.26 | 0.24 | 0.23 | 0.2 | 0.21 | |
| Intangibles to total assets | 0.09 | 0.1 | 0.1 | 0.09 | 0.09 | |
| Capex to operating cash flow | -1.9 | -0.44 | -0.3 | -0.27 | -0.2 | |
| Capex to revenue | -0.11 | -0.1 | -0.08 | -0.07 | -0.03 | |
| Capex to depreciation | -3.24 | -2.79 | -1.58 | -1.28 | -0.69 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.49K | 1.56K | 1.72K | 2.08K | 2.18K | |
| ROIC | 0.11 | 0.11 | 0.13 | 0.15 | 0.15 | |
| Return on tangible assets | 0.09 | 0.09 | 0.1 | 0.11 | 0.12 | |
| Graham Net | 42.08 | -8.64 | 22.72 | 37.8 | 120.91 | |
| Working capital | 141B | 111.47B | 133.89B | 153.91B | 215.34B | |
| Tangible asset value | 473.9B | 499.68B | 501.59B | 570.84B | 596.94B | |
| Net current asset value | 129.86B | 102.3B | 119.8B | 141.96B | 203.74B | |
| Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 36.59B | 38B | 36.8B | 39.16B | 44.43B | |
| Average inventory | 35.22B | 35.99B | 36.03B | 39.15B | 40.48B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 189.87 | 160.37 | 158.99 | 167.04 | 193.95 | |
| Days of inventory on hand | 174.65 | 142.91 | 151.91 | 166.99 | 163.22 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 1.92 | 2.28 | 2.3 | 2.19 | 1.88 | |
| Inventory turnover | 2.09 | 2.55 | 2.4 | 2.19 | 2.24 | |
| ROE | 0.1 | 0.09 | 0.11 | 0.12 | 0.12 | |
| Capex per share | -57.56 | -57.58 | -44.54 | -40.66 | -24.6 |
Quarterly Fundamentals Overview
Last date of statement is 2022-06-30 for Q1
| Metric | History | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 |
|---|---|---|---|---|---|---|
| Revenue per share | 175.02 | 173.72 | 195.59 | 180.68 | 218.58 | |
| Net income per share | 48.23 | 44.51 | 36.83 | 31.94 | 60.37 | |
| Operating cash flow per share | 13.54 | 67.34 | -26.06 | 69.18 | 67.75 | |
| Free cash flow per share | 0.92 | 62.66 | -29.25 | 65.04 | 60.02 | |
| Cash per share | 184.6 | 259.21 | 221.51 | 235 | 278.93 | |
| Book value per share | 1.29K | 1.35K | 1.33K | 1.32K | 1.38K | |
| Tangible book value per share | 1.16K | 1.22K | 1.2K | 1.2K | 1.26K | |
| Share holders equity per share | 1.29K | 1.35K | 1.33K | 1.32K | 1.38K | |
| Interest debt per share | 18.34 | 18.06 | 18.28 | 18.73 | 18.29 | |
| Market cap | 1237.38B | 1274.36B | 1421.52B | 1536.99B | 1700.07B | |
| Enterprise value | 1196.77B | 1202.2B | 1368.14B | 1476.68B | 1620.77B | |
| P/E ratio | 12.85 | 14.34 | 19.39 | 24.17 | 14.42 | |
| Price to sales ratio | 14.16 | 14.7 | 14.6 | 17.09 | 15.93 | |
| POCF ratio | 183.15 | 37.91 | -109.59 | 44.64 | 51.4 | |
| PFCF ratio | 2.68K | 40.75 | -97.64 | 47.48 | 58.01 | |
| P/B Ratio | 1.92 | 1.89 | 2.15 | 2.34 | 2.53 | |
| PTB ratio | 1.92 | 1.89 | 2.15 | 2.34 | 2.53 | |
| EV to sales | 13.7 | 13.86 | 14.05 | 16.42 | 15.19 | |
| Enterprise value over EBITDA | 33.84 | 36.57 | 46.36 | 57.42 | 37.2 | |
| EV to operating cash flow | 177.14 | 35.77 | -105.48 | 42.89 | 49 | |
| EV to free cash flow | 2.6K | 38.44 | -93.97 | 45.61 | 55.31 | |
| Earnings yield | 0.02 | 0.02 | 0.01 | 0.01 | 0.02 | |
| Free cash flow yield | 0 | 0.02 | -0.01 | 0.02 | 0.02 | |
| Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Debt to assets | 0.12 | 0.12 | 0.1 | 0.1 | 0.11 | |
| Net debt to EBITDA | -1.15 | -2.2 | -1.81 | -2.35 | -1.82 | |
| Current ratio | 3.01 | 3.4 | 4.34 | 4.27 | 4.16 | |
| Interest coverage | 98.32 | 489.29 | 0 | 40.36 | 136.78 | |
| Income quality | 0.28 | 1.51 | -0.71 | 2.17 | 1.12 | |
| Dividend Yield | 0.01 | 0 | 0.01 | 0 | 0.01 | |
| Payout ratio | 0.53 | 0.05 | 0.72 | 0.05 | 0.43 | |
| Sales general and administrative to revenue | 0.22 | 0.22 | 0.2 | 0.22 | 0.2 | |
| Research and developement to revenue | 0.17 | 0.2 | 0.17 | 0.29 | 0.18 | |
| Intangibles to total assets | 0.1 | 0.09 | 0.09 | 0.09 | 0.08 | |
| Capex to operating cash flow | -0.93 | -0.07 | 0.12 | -0.06 | -0.11 | |
| Capex to revenue | -0.07 | -0.03 | -0.02 | -0.02 | -0.04 | |
| Capex to depreciation | -1.47 | -0.53 | -0.36 | -0.44 | -0.88 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 1.18K | 1.16K | 1.05K | 973.2 | 1.37K | |
| ROIC | 0.05 | 0.04 | 0.04 | 0.03 | 0.06 | |
| Return on tangible assets | 0.04 | 0.03 | 0.03 | 0.02 | 0.04 | |
| Graham Net | 38.33 | 111.15 | 112.59 | 121.25 | 145.46 | |
| Working capital | 162.8B | 194.9B | 206.79B | 215.34B | 237B | |
| Tangible asset value | 576.95B | 608.02B | 596.07B | 596.94B | 614.58B | |
| Net current asset value | 150.93B | 182.91B | 194.96B | 203.74B | 225.52B | |
| Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 41.11B | 40.62B | 44.3B | 49.69B | 45.67B | |
| Average inventory | 40.63B | 40.21B | 40.43B | 41.82B | 42.23B | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 128.44 | 124.74 | 139.67 | 195.48 | 139.18 | |
| Days of inventory on hand | 155.73 | 152.56 | 140.15 | 164.51 | 142.47 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0.7 | 0.72 | 0.64 | 0.46 | 0.65 | |
| Inventory turnover | 0.58 | 0.59 | 0.64 | 0.55 | 0.63 | |
| ROE | 0.04 | 0.03 | 0.03 | 0.02 | 0.04 | |
| Capex per share | -12.61 | -4.68 | -3.19 | -4.13 | -7.73 |
Frequently Asked Questions
What is Ono Pharmaceutical Co., Ltd. stock symbol ?
Ono Pharmaceutical Co., Ltd. is a JP stock and trading under the symbol 4528.T
What is Ono Pharmaceutical Co., Ltd. stock quote today ?
Ono Pharmaceutical Co., Ltd. stock price is $3381 today.
Is Ono Pharmaceutical Co., Ltd. stock public?
Yes, Ono Pharmaceutical Co., Ltd. is a publicly traded company.
Company Profile
- Volume Average 1.49M
- Market Capitalization 1650.98B
- Employee 3.69K
- Headquarters Osaka,JP
- IPO Date 2001-01-04
-
Website
https://www.ono-pharma.com 
Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers OPDIVO intravenous infusions for the treatment of malignant tumors; KYPROLIS for intravenous injection; EMEND capsules/PROEMEND intravenous injections for chemotherapy-induced nausea and vomiting; DEMSER capsules for improvement of the symptoms in patients with pheochromocytoma; and MEKTOVI, VELEXBRU, and ADLUMIZ tablets, as well as BRAFTOVI capsules for malignant tumors. The company also provides GLACTIV and FORXIGA tablets for type 2 diabetes; FORXIGA tablets for the treatment of diabetes; ONOACT injections for tachyarrhythmia; OPALMON tablets to treat peripheral circulatory disorder; CORALAN for treatment of chronic heart failure; ORENCIA injections for rheumatoid arthritis; RIVASTACH patches for Alzheimer's disease; ONGENTYS tablets for the treatment of Parkinson's disease; PARSABIV, an intravenous injection for dialysis patients; STAYBLA tablets for overactive bladder; ONON capsules and dry syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as RECALBON tablets for osteoporosis. In addition, it is developing products for esophageal, urothelial carcinoma, Hodgkin's lymphoma, ovarian, bladder, prostate, hepatocellular carcinoma, pancreatic, biliary tract, virus positive/negative solid carcinoma, gastric, esophageal, urothelial, hepatocellular, thyroid, colorectal, melanoma, acute myeloid leukemia, non-small cell lung cancer, primary central nervous system lymphoma, myelodysplastic syndrome, polymyositis/dermatomyositis, tachyarrhythmia, pemphigus, generalized scleroderma, enthesopathy, diabetic polyneuropathy, neurodegenerative, autoimmune, narcolepsy, and thrombosis. The company was founded in 1717 and is headquartered in Osaka, Japan.
